IRIS
GATTO, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.541
NA - Nord America 1.643
AS - Asia 1.301
Continente sconosciuto - Info sul continente non disponibili 322
SA - Sud America 121
AF - Africa 19
OC - Oceania 1
Totale 11.948
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.294
US - Stati Uniti d'America 1.522
SG - Singapore 471
CN - Cina 299
VN - Vietnam 218
BD - Bangladesh 187
BR - Brasile 80
FR - Francia 78
CA - Canada 45
FI - Finlandia 45
HK - Hong Kong 43
GB - Regno Unito 33
DE - Germania 31
MX - Messico 18
IQ - Iraq 14
AR - Argentina 13
JP - Giappone 11
IE - Irlanda 10
JM - Giamaica 10
PH - Filippine 10
CR - Costa Rica 9
CO - Colombia 8
ID - Indonesia 8
IN - India 8
NL - Olanda 8
VE - Venezuela 8
SV - El Salvador 7
CH - Svizzera 6
ES - Italia 6
GT - Guatemala 6
NI - Nicaragua 6
ZA - Sudafrica 6
EC - Ecuador 5
HN - Honduras 5
RU - Federazione Russa 5
TR - Turchia 5
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
MA - Marocco 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
UA - Ucraina 3
AT - Austria 2
AZ - Azerbaigian 2
BB - Barbados 2
BE - Belgio 2
BG - Bulgaria 2
BY - Bielorussia 2
BZ - Belize 2
CW - ???statistics.table.value.countryCode.CW??? 2
DZ - Algeria 2
IL - Israele 2
KZ - Kazakistan 2
NP - Nepal 2
PL - Polonia 2
PR - Porto Rico 2
PT - Portogallo 2
SC - Seychelles 2
SE - Svezia 2
AG - Antigua e Barbuda 1
AL - Albania 1
AU - Australia 1
BO - Bolivia 1
CU - Cuba 1
DJ - Gibuti 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GY - Guiana 1
HR - Croazia 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LT - Lituania 1
MM - Myanmar 1
MQ - Martinica 1
MU - Mauritius 1
MY - Malesia 1
NE - Niger 1
NG - Nigeria 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UZ - Uzbekistan 1
VI - Stati Uniti Isole Vergini 1
Totale 11.628
Salva come PNG Salva come JPEG
Città #
Genova 3.923
Genoa 2.761
Vado Ligure 821
Rapallo 520
San Jose 355
Singapore 226
Ashburn 166
Council Bluffs 69
Lauterbourg 68
Ho Chi Minh City 59
Hanoi 54
New York 53
Beijing 47
Hong Kong 39
Santa Clara 35
Milan 34
Helsinki 33
Los Angeles 28
Phoenix 27
Boardman 24
Rome 23
Frankfurt am Main 19
Chicago 18
Newark 15
Philadelphia 15
Bologna 14
Haiphong 14
San Francisco 13
Hamilton 12
Lappeenranta 12
Atlanta 11
Brooklyn 11
St Louis 11
Tokyo 11
Bordighera 10
Ilion 10
Naples 10
Orem 10
Turin 10
Montreal 9
Buffalo 8
City of London 8
Da Nang 8
Dallas 8
Dublin 8
Kingston 8
London 8
Mexico City 8
Toronto 8
Memphis 7
Biên Hòa 6
Houston 6
Managua 6
San José 6
San Salvador 6
São Paulo 6
Birmingham 5
Can Tho 5
Carrabelle 5
Charlotte 5
Denver 5
Fayetteville 5
Fort Myers 5
Hayward 5
Johannesburg 5
Odessa 5
Seattle 5
Spokane 5
Zurich 5
Baghdad 4
Brasília 4
Bristol 4
Cleveland 4
Corona 4
Des Moines 4
Florence 4
Fort Lauderdale 4
Guatemala City 4
Hải Dương 4
Miami 4
Middletown 4
Modena 4
Ninh Bình 4
Nuremberg 4
Piscataway 4
Reggio Emilia 4
Salt Lake City 4
Shanghai 4
Strafford 4
Thái Nguyên 4
Tianjin 4
Albignasego 3
Bogotá 3
Brescia 3
Catania 3
Cincinnati 3
Curitiba 3
Greensboro 3
Hamburg 3
Hyattsville 3
Totale 9.895
Salva come PNG Salva come JPEG
Nome #
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 250
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 230
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 227
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 216
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 216
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 215
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management 213
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 197
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 194
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 193
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 193
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 190
Hormone receptors analysis in idiopathic progressive subglottic stenosis 188
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 186
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 186
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 184
Aggressive and malignant prolactinomas 177
Somatostatin receptor scintigraphy in thoracic diseases 163
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 163
Somatostatin receptor ligands in the treatment of acromegaly 163
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 163
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 161
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature 160
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 159
Does pasireotide directly modulate skeletal muscle metabolism? 158
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 157
Emerging drugs for the treatment of acromegaly 157
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 156
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 153
OR2,6 Interrelationship between somatostatin/dopamine pathways and growth factors in non-small lung cancer cells 151
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 150
Diagnosis and Treatment of Parasellar Lesions 147
Regulation Of Prostate Cancer Cell Proliferation By Somatostatin Receptor Activation 144
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review 142
P87 Effect of exenatide, sitagliptin and vildagliptin on IGF-I in diabetic patients 142
In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5 142
The role of somatostatin and dopamine D2 receptors in endocrine tumors 138
Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia 137
Abstracts of the 6th Annual ENETS Conference, Granada, Spain, March 5–7, 2009 137
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives 137
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas 136
Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment 135
An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report 134
Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients 132
Modulatory activity of testosterone on growth pattern and IGF-1 levels in vanishing testis syndrome: a case report during 15 years of follow-up 132
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for 132
Novel chimeric somatostatin analogs: facts and perspectives 132
Body Composition and Bone Status in Relation to Microvascular Damage in Systemic Sclerosis Patients 132
Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: implications for the in vivo visualization during somatostatin receptor scintigraphy. 131
Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective 129
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experience 125
Extraintestinal precoccygeal tumour with endocrine features and its relationship with Currarino syndrome. 125
Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone–secreting pituitary tumors 120
Ultra-short antibiotic prophylaxis guided by preoperative microbiological nasal swabs in endoscopic endonasal skull base surgery 116
Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism 112
null 110
null 110
null 109
The effect of sodium restriction on iodine prophylaxis: a review 109
Novel Molecular Mechanisms of Resistance to Somatostatin Analog Treatment in Pituitary Adenomas 107
GH Replacement in the Elderly: Is It Worth It? 107
Challenging diagnosis of resistance to thyroid hormone in a patient with COVID-19, pituitary microadenoma and unusual response to octreotide long-acting release test 104
null 104
Sodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real Villain 90
Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge 89
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients 87
Somatostatin receptors and the associated intracellular machinery: the two sides of the coin 85
Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients 85
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study 83
Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH/PRL-secreting pituitary tumors 83
Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors 83
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 80
Corrigendum to "Regulation of prostate cancer cell proliferation by somatostatin receptor activation" [Mol. Cell. Endocrinol. 315 (1-2) (2010) 254-262] 80
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression 76
Cushing's syndrome 71
Left ventricular mass reduction by a low-sodium diet in treated hypertensive patients 71
Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length 66
Skeletal Muscle Evaluation in Patients With Acromegaly 66
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids 65
Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide 63
null 61
Who and how to screen for Cushing’s syndrome: the position statement of the Italian Society of Endocrinology 60
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. 58
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism 53
Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. 53
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1 48
Impact of Nutrition on Somatotroph Axis: A Potential Role in Acromegaly and Its Cardiovascular Risk? 45
Editorial: Resistance to Medical Therapy in Pituitary Tumors 45
Octreotide-resistant acromegaly: Challenges and solutions 41
Gender differences in the glycometabolic and cardiovascular features of acromegaly 41
La composizione dei macronutrienti nella dieta influenza l’asse somatotropo: un potenziale trattamento per l’acromegalia? 38
Metabolic syndrome in cushing’s syndrome patients: Does gender matter? 36
Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN) 35
Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence? 32
European survey on metabolic and cardiovascular risk in Cushing syndrome 30
Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey 29
Hypopituitarism in patients with prolactinomas: a narrative review 28
null 28
Global epidemiology of acromegaly: a systematic review and meta-analysis 28
Somatostatin receptor pathophysiology in the neuroendocrine system 27
Totale 11.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.961
article - articoli 39.035
book - libri 313
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 613
Totale 79.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022679 0 0 80 95 26 56 26 166 51 61 26 92
2022/2023641 56 62 5 47 68 105 18 41 118 11 98 12
2023/2024502 25 54 10 61 29 87 42 24 27 39 37 67
2024/20251.994 71 131 59 146 263 219 191 316 73 84 201 240
2025/20263.850 405 86 348 337 414 289 488 156 303 373 262 389
2026/2027898 459 201 238 0 0 0 0 0 0 0 0 0
Totale 11.948